Weighty Matters: Balancing Weight Gain with Cardiovascular Risk among Patients with Type 1 Diabetes on Intensive Insulin Therapy
Type 1 diabetes, characterized by a deficiency of insulin production due to damaged pancreatic beta cells, is associated with a 10-fold increase in the risk of cardiovascular disease as compared to the general population.1,2 Intensive insulin therapy, whether administered by multiple daily injections or continuous infusion via a pump, is the cornerstone of glycemic control in the patient with type 1 diabetes.3 Most of what we know regarding the benefits of intensive insulin therapy is derived from the Diabetes Control and Complications Trial (DCCT), a trial of patients with type 1 diabetes who were randomized to either intensive or conventional insulin treatment.
- Received November 26, 2012.
- Accepted November 27, 2012.
- Copyright © 2012, American Heart Association, Inc. All rights reserved. Unauthorized use prohibited